Alkermes - ALKS Stock Forecast, Price & News

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; VIVITROL for the treatment of alcohol and prevention of opioid dependence; RISPERDAL CONSTA for the treatment of schizophrenia and bipolar I disorder; INVEGA SUSTENNA for the treatment of schizophrenia and schizoaffective disorder; XEPLION, INVEGA TRINZA, and TREVICTA to treat schizophrenia and schizoaffective; and VUMERITY for the treatment of relapsing forms of multiple sclerosis in adults, including clinically isolated syndrome, relapsing-remitting and active secondary progressive diseases. The company is also developing LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder; and nemvaleukin alfa, an engineered fusion protein to expand tumor-killing immune cells and to avoid the activation of immunosuppressive cells. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.

Wall Street Analysts Forecast Growth

A number of research firms recently weighed in on ALKS. Piper Sandler assumed coverage on Alkermes in a report on Tuesday. They issued a "neutral" rating and a $26.00 price target on the stock. HC Wainwright increased their target price on Alkermes from $30.00 to $32.00 in a report on Thursday, April 28th. StockNews.com upgraded Alkermes from a "buy" rating to a "strong-buy" rating in a report on Thursday, July 28th. The Goldman Sachs Group began coverage on Alkermes in a research note on Wednesday, April 20th. They set a "buy" rating and a $35.00 price target on the stock. Finally, Stifel Nicolaus increased their price target on Alkermes to $28.00 in a research note on Wednesday, July 27th. One research analyst has rated the stock with a sell rating, five have given a hold rating, four have assigned a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat, the stock has a consensus rating of "Hold" and a consensus price target of $30.10.

Alkermes Trading Down 0.6 %

Shares of ALKS opened at $26.45 on Wednesday. The company has a current ratio of 2.39, a quick ratio of 2.03 and a debt-to-equity ratio of 0.27. The firm has a market capitalization of $4.34 billion, a P/E ratio of -46.40 and a beta of 0.60. The stock's fifty day simple moving average is $28.42 and its 200 day simple moving average is $27.44. Alkermes has a twelve month low of $21.24 and a twelve month high of $33.00.

Alkermes (NASDAQ:ALKS - Get Rating) last announced its quarterly earnings results on Wednesday, July 27th. The company reported $0.06 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.01 by $0.05. Alkermes had a positive return on equity of 0.79% and a negative net margin of 8.02%. The firm had revenue of $276.22 million during the quarter, compared to the consensus estimate of $269.01 million. During the same period in the prior year, the firm earned $0.13 EPS. The firm's quarterly revenue was down 9.1% compared to the same quarter last year. On average, equities research analysts forecast that Alkermes will post -0.35 earnings per share for the current year.

Insider Activity at Alkermes

In related news, SVP Christian Todd Nichols sold 7,474 shares of the stock in a transaction on Tuesday, June 21st. The stock was sold at an average price of $28.26, for a total value of $211,215.24. Following the completion of the sale, the senior vice president now directly owns 21,035 shares in the company, valued at approximately $594,449.10. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. 4.76% of the stock is owned by insiders.